Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Terminal complement pathway deficiency
Terminal complement pathway deficiency is a genetic condition affecting the complement membrane attack complex (MAC).
It involves deficiencies of C5, C6, C7, and C8. (While C9 is part of the MAC, and deficiencies have been identified, it is not required for cell lysis.)
People with this condition are prone to meningococcal infection. Vaccination may be recommended.
Suspect terminal complement pathway deficiency in patients with more than one Neisseria infection episode.
Initial complement tests often include C3 and C4, but not C5 through C9. Instead, the CH50 result may play a role in diagnosis: if the CH50 level is low but C3 and C4 are normal, then analysis of the individual terminal components may be warranted.
Patients with terminal complement pathway deficiency should receive meningococcal and pneumococcal vaccinations. They can receive live vaccines.
Hub AI
Terminal complement pathway deficiency AI simulator
(@Terminal complement pathway deficiency_simulator)
Terminal complement pathway deficiency
Terminal complement pathway deficiency is a genetic condition affecting the complement membrane attack complex (MAC).
It involves deficiencies of C5, C6, C7, and C8. (While C9 is part of the MAC, and deficiencies have been identified, it is not required for cell lysis.)
People with this condition are prone to meningococcal infection. Vaccination may be recommended.
Suspect terminal complement pathway deficiency in patients with more than one Neisseria infection episode.
Initial complement tests often include C3 and C4, but not C5 through C9. Instead, the CH50 result may play a role in diagnosis: if the CH50 level is low but C3 and C4 are normal, then analysis of the individual terminal components may be warranted.
Patients with terminal complement pathway deficiency should receive meningococcal and pneumococcal vaccinations. They can receive live vaccines.